Takeda Pharmaceutical enzyme replacement drug Adzynma is the first FDA-approved therapy for a rare blood disorder affecting fewer than 1,000 Americans. Our regulatory recap also includes the much-anticipated approval of an Eli Lilly weight loss drug and a crackdown on what the FTC says are improperly listed pharma product patents.
More funding and another powerful pharma backer have entered the microbiome space, showing that at least some investors and pharma execs believe the field can begin converting preclinical ideas into valid human therapies.
Explore top-tier aesthetic certification programs that blend theory with hands-on training — perfect for health care pros ready to elevate their practice
Koneksa Health CEO Chris Benko said he views the natural place for the use of these technologies in clinical studies either in early phases or as an exploratory addition in later phases in a phone interview with MedCity News.
Takeda Pharmaceuticals launches what it bills as the largest pharma company-sponsored observational study in mutiple myeloma that aims to enroll up to 5,000 patients worldwide and follow them for a minimum of five years.
Also, research scientists have developed a way to deliver drugs through the placenta and what risks does the UK life science community face with an exit from the European Union?
Aquinnah's approach targets a protein called TDP-43 that has been found to accumulate in patients with neurodegenerative conditions like ALS, Alzheimer's disease and certain dementias.
A new report by Paubox calls for healthcare IT leaders to dispose of outdated assumptions about email security and address the challenges of evolving cybersecurity threats.
Takeda announced positive late-stage results for its new type 2 diabetes drug, fasiglifam (TAK-875), the first GPR40 agonist to reach late-stage development. Fasiglifam has the potential to be a compelling therapeutic option and will likely be investigated for use in combination therapy, given its unique mechanism of action. The Japanese drug maker is in desperate […]
Type 2 diabetes drug alogliptin may have fallen short of regulatory approval in the United States, but its latest progress overseas is paying off for Furiex Pharmaceuticals (NASDAQ:FURX) in the form of a $10 million milestone payment. The marketing authorization application filed by drug partner Takeda Pharmaceutical (TYO:4502) was accepted and triggered the payment to […]
Takeda Pharmaceuticals is a strategic investor in regenerative medicine company Juventas Therapeutics’ upcoming series B round of funding. Juventas’ CEO Rahul Aras discussed the investment during a panel at a meeting of the Ohio Venture Association on Friday. “If you think venture capital due diligence is difficult …” Aras joked, “I think [Takeda] called my […]
Today we might glimpse the U.S. Food and Drug Administration’s thoughts on approving new type 2 diabetes drugs in a post-Avandia world. Nesina, a Takeda Pharmaceutical (TYO:4502) compound licensed from Furiex Pharmaceuticals (NASDAQ:FURX), is set for a prescription drug user fee act (PDUFA) decision today. The drug candidate, also known as alogliptin, was developed to […]
In today’s healthcare landscape, your choice of medical billing partner directly impacts your bottom line. What are the best medical billing outsourcing companies, and which one is right for you?
Takeda Pharmaceutical Co. has agreed to acquire an East Coast pharmaceutical firm with a gout treatment as its lead drug in a deal valued at more than $800 million. Takeda said it made the deal to bolster its gout treatment portfolio. Takeda is one of the largest pharmaceuticals companies in Asia and is acquiring URL […]
Furiex Pharmaceuticals (NASDAQ:FURX) must wait until April to learn whether the type 2 diabetes compound it licensed to a drug partner will secure regulatory approval and a $25 million milestone payment for the company. The U.S. Food and Drug Administration has notified drug partner Takeda Pharmaceuticals that review of investigational diabetes drug alogliptin has been […]